{"id":50162,"key":"Global_Health_Medical_Device_Compendium/VISITECT®_CD4","title":"Global Health Medical Device Compendium/VISITECT® CD4","latest":{"id":1267602,"timestamp":"2026-09-10T13:53:07Z"},"content_model":"wikitext","license":{"url":"https://www.appropedia.org/Appropedia:Copyrights","title":"CC-BY-SA-4.0"},"source":"[[File:VISITECT.jpg|thumb]]\n\n{{GHMDC device data\n| health-topic = HIV/AIDS\n| classification = Diagnosis\n| scope = Clinical trial\n| manufacturer-location = Australia\n| manufacturer-coordinates = 24° 46' 33.99\" S, 134° 45' 18.00\" E\n}}\n\nHigh rates of HIV infection in the developing world hinders improvements in maternal mortality and also contributes to poor perinatal health outcomes such as stillbirth, preterm birth, and low birth weight. HIV infection of infants and HIV-related maternal deaths are largely due to the delayed initiation of antiretroviral interventions. In addition to mother-to-child transmission of the HIV virus, HIV still remains widespread in low-resource settings.\n\n== Detailed description of the solution ==\n\nThe VISITECT® CD4 enables CD4+ T-cell levels to be determined quickly and conveniently through a finger prick sample. The tests itself only costs US $2, does not require any instrumentation or electricity, and takes forty minutes to yield the results. By assessing CDF count at the first antenatal visit using VISITECT® CD4, pregnant women undergoing the test can receive same day initiation of the most appropriate lifesaving antiretroviral intervention. Administrating antiretroviral intervention early on in the pregnancy not only will benefit the mother's health but will help prevent mother-to-child transmission of the HIV virus, significantly reducing maternal and infant deaths.\n\n== Designed by ==\n\n* Designed by: David Anderson from Burnet Institute\n* Manufacturer (if different):\n* Manufacturer location: Australia\n\n== When and where it was tested/implemented ==\n\nPapua New Guinea, Kenya, South Africa\n\n== Funding Source ==\n\nFinalist of Saving Lives at Birth Competition\n\n== References ==\n\n=== Peer-reviewed publication ===\n\n=== Other internally generated reports ===\n\nParish, T. (July 18, 2012). Project nominated for \"Saving Lives at Birth\" award. Retrieved from http://www.burnet.edu.au/news/140_project_nominated_for_saving_lives_at_birth_award\n\nParish, T. (July 26, 2012). Six years in the making: Cd4 test officially launched!. Retrieved from http://www.burnet.edu.au/news/149_six_years_in_the_making_cd4_test_officially_launched\n\nVISITECT® CD4. Retrieved from http://www.omegadiagnostics.com/cd4/\n\n=== Externally generated reports ===\n\nPerformance of an innovative, instrument-free, low-cost, rapid point-of-care cd4 test for accelerating initiation of antiretroviral interventions for HIV 1-infected pregnant women in resource-constrained settings. (August 06, 2012). Retrieved from http://web.archive.org/web/20160507174523/https://savinglivesatbirth.net/summaries/191\n\n=== IP and copyright ===\n\n=== Approval by regulatory bodies or standards boards ===\n\n{{Page data\n| license = CC-BY-SA-4.0\n| description = VISITECT® CD4 helps track immune health for HIV care. Appropedia shows how this rapid test supports treatment in low-resource settings.\n}}"}